Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto A Escala-Cornejo

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
JCO Oncology Practice|May 6, 2020
Management of Febrile Neutropenia Associated With SARS-CoV-2 Infection in a Patient With CancerLuis Figuero-Pérez, Alejandro Olivares-Hernández, Roberto A Escala-Cornejo, et al.
Reumatologia Clinica|June 27, 2022
Use of anakinra in the treatment of SARS-CoV-2 severe respiratory infectionLuis Figuero-Pérez, Alejandro Olivares-Hernández, Roberto A Escala-Cornejo, et al.
JCO Oncology Practice|September 3, 2020
Reply to A. Lasagna et alLuis Figuero-Pérez, Alejandro Olivares-Hernández, Roberto A Escala-Cornejo, et al.
Reumatologia Clinica|March 21, 2022
[Use of anakinra in the treatment of SARS-CoV-2 severe respiratory infection]Luis Figuero-Pérez, Alejandro Olivares-Hernández, Roberto A Escala-Cornejo, et al.
Reumatologia Clinica|November 26, 2021
Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumabLuis Figuero-Pérez, Alejandro Olivares-Hernández, Roberto A Escala-Cornejo, et al.
Reumatologia Clinica|June 24, 2020
Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumabLuis Figuero-Pérez, Alejandro Olivares-Hernández, Roberto A Escala-Cornejo, et al.
Annals of Nuclear Medicine|July 28, 2018
Large cell neuroendocrine carcinoma of the lung with atypical evolution and a remarkable response to lutetium Lu 177 dotatateRoberto A Escala Cornejo, Paloma García-Talavera, Miguel Navarro Martin, et al.
Case Reports in Oncological Medicine|February 25, 2021
Response to Treatment with an Anti-Interleukin-6 Receptor Antibody (Tocilizumab) in a Patient with Hemophagocytic Syndrome Secondary to Immune Checkpoint InhibitorsAlejandro Olivares-Hernández, Luis Figuero-Pérez, María A Amores Martín, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
JCO Oncology Practice|May 6, 2020
Management of Febrile Neutropenia Associated With SARS-CoV-2 Infection in a Patient With CancerLuis Figuero-Pérez, Alejandro Olivares-Hernández, Roberto A Escala-Cornejo, et al.
Reumatologia Clinica|June 27, 2022
Use of anakinra in the treatment of SARS-CoV-2 severe respiratory infectionLuis Figuero-Pérez, Alejandro Olivares-Hernández, Roberto A Escala-Cornejo, et al.
JCO Oncology Practice|September 3, 2020
Reply to A. Lasagna et alLuis Figuero-Pérez, Alejandro Olivares-Hernández, Roberto A Escala-Cornejo, et al.
Reumatologia Clinica|March 21, 2022
[Use of anakinra in the treatment of SARS-CoV-2 severe respiratory infection]Luis Figuero-Pérez, Alejandro Olivares-Hernández, Roberto A Escala-Cornejo, et al.
Reumatologia Clinica|November 26, 2021
Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumabLuis Figuero-Pérez, Alejandro Olivares-Hernández, Roberto A Escala-Cornejo, et al.
Reumatologia Clinica|June 24, 2020
Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumabLuis Figuero-Pérez, Alejandro Olivares-Hernández, Roberto A Escala-Cornejo, et al.
Annals of Nuclear Medicine|July 28, 2018
Large cell neuroendocrine carcinoma of the lung with atypical evolution and a remarkable response to lutetium Lu 177 dotatateRoberto A Escala Cornejo, Paloma García-Talavera, Miguel Navarro Martin, et al.
Case Reports in Oncological Medicine|February 25, 2021
Response to Treatment with an Anti-Interleukin-6 Receptor Antibody (Tocilizumab) in a Patient with Hemophagocytic Syndrome Secondary to Immune Checkpoint InhibitorsAlejandro Olivares-Hernández, Luis Figuero-Pérez, María A Amores Martín, et al.
Pageof 1